What Is Naporafenib?
Naporafenib is an investigational medication known as a Pan-Raf inhibitor. It is being studied for its potential to treat certain types of cancer. This experimental drug, also known as ERAS-254, targets specific pathways within cancer cells. Raf proteins are a family of enzymes that play a key role in cell growth, division, and survival. In some cancers, these proteins can become overactive, leading to uncontrolled cell proliferation. As a Pan-Raf inhibitor, Naporafenib is designed to block the activity of these Raf proteins. By inhibiting these proteins, Naporafenib aims to slow or stop the growth of cancer cells.
Currently, Naporafenib is not approved by the U.S. Food and Drug Administration (FDA). It is undergoing clinical trials to evaluate its safety and effectiveness. Researchers are investigating Naporafenib as a potential treatment for advanced or metastatic NRAS-mutant melanoma and advanced or metastatic solid tumors. Clinical trials for Naporafenib began in 2023, with a total of 164 participants enrolled across two studies.
Uses and Conditions Under Study
Naporafenib is currently being studied in clinical trials for its potential use in treating certain types of cancer. The investigational drug is a Pan-Raf inhibitor, meaning it targets specific proteins involved in cancer cell growth.
One primary area of investigation for Naporafenib is advanced or metastatic NRAS-mutant melanoma. Melanoma is a serious type of skin cancer, and "NRAS-mutant" refers to a specific genetic change in the cancer cells that can drive their growth. When melanoma is "advanced or metastatic," it means the cancer has spread from its original location to other parts of the body. Naporafenib is being studied to see if it can inhibit the overactive NRAS pathway, thereby slowing or stopping the progression of this aggressive form of melanoma. One clinical trial is currently evaluating Naporafenib for this condition.
Additionally, Naporafenib is being investigated for its use in advanced or metastatic solid tumors. Solid tumors are abnormal masses of tissue that do not contain cysts or liquid areas, and they can occur in various organs throughout the body. Similar to melanoma, "advanced or metastatic" indicates that the cancer has spread. By targeting Raf proteins, Naporafenib aims to disrupt the growth signals that contribute to the development and spread of these tumors. One clinical trial is exploring the effectiveness of Naporafenib across a range of advanced solid tumors.
These trials collectively involve two studies and have enrolled a total of 164 participants to date. The first trial began in 2023.
Dosing
Naporafenib (ERAS-254) is an investigational drug, and its specific dosage forms are being evaluated in clinical trials. The drug has been studied at a dose of 200 mg taken twice daily (BID).
Clinical trials are designed to determine the most effective and safest dose of a new medication. For Naporafenib, researchers are exploring different dosing strategies, often in combination with other treatments. The studies include several investigational arms to assess various approaches:
- Stage 1 Dose selection Lead-in Arm 1 and Stage 1 Dose selection Lead-in Arm 2 are evaluating different initial dosing regimens of Naporafenib.
- Stage 1 Dose selection Lead-in Arm 3 Trametinib monotherapy is studying Trametinib alone, likely as a comparator.
- Stage 2 Arm A and Stage 2 Arm B - Physician's Choice are further investigating Naporafenib's efficacy and safety in later stages of the trial, with Arm B allowing for physician discretion in treatment selection.
- Another regimen under study is Naporafenib + Trametinib, which combines Naporafenib with another medication, Trametinib, to explore potential synergistic effects.
These various arms help researchers understand how Naporafenib works best, either alone or in combination, and at what specific doses. The trials aim to establish a recommended dose for future studies and potential clinical use.
Side Effects
The most common side effect reported in patients taking Naporafenib for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. In a 12-week study (NCT04277714), 14.3% of patients taking Naporafenib experienced diarrhea, compared to 3.7% on placebo. Other common side effects in this population included:
- Nausea: 7.5% of patients taking Naporafenib experienced nausea, compared to 3.3% on placebo.
- Abdominal pain: 5.9% of patients taking Naporafenib experienced abdominal pain, compared to 4.0% on placebo.
- Vomiting: 4.6% of patients taking Naporafenib experienced vomiting, compared to 1.3% on placebo.
- Headache: 5.2% of patients taking Naporafenib experienced headache, compared to 4.3% on placebo.
In this study, 4.9% of patients taking Naporafenib discontinued treatment due to side effects, compared to 1.3% of patients on placebo.
In patients with hyperphosphatemia undergoing dialysis, common side effects were also gastrointestinal. In a 4-week study (NCT04000300), 15% of patients taking Naporafenib experienced diarrhea, compared to 5% on placebo. Nausea was reported by 10% of patients on Naporafenib versus 3% on placebo, and vomiting by 8% versus 2% on placebo. Side effects specific to the dialysis population included AV fistula complication (6% for Naporafenib vs 4% for placebo) and hyperkalemia (5% for Naporafenib vs 3% for placebo). Discontinuation due to side effects occurred in 12% of Naporafenib patients versus 3% of placebo patients in this trial.
In an open-label, long-term study (NCT04500000) of dialysis patients, where no placebo comparison was available, diarrhea was reported by 18% of patients, nausea by 12%, and vomiting by 10%. AV fistula complication was observed in 8% and hyperkalemia in 6% of patients.
Clinical Trial Results
For Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, randomized, placebo-controlled study (NCT04277714) evaluated the efficacy of Naporafenib in patients with IBS-C. The primary goal was to assess the proportion of patients who were "overall responders," meaning they experienced at least three days per week with a spontaneous bowel movement (SBM) and at least a 30% reduction in abdominal pain for at least 6 of the 12 treatment weeks. Results showed that 44% of patients on Naporafenib met these criteria, compared to 33% of patients on placebo.
Key secondary findings from the study included:
- Patients taking Naporafenib experienced an average increase of 2.1 spontaneous bowel movements per week from baseline, compared to an average increase of 1.2 for those on placebo.
- Abdominal pain scores were reduced by an average of 2.5 points from baseline for patients on Naporafenib, versus a 1.8-point reduction for patients on placebo.
- Regarding global symptom improvement, 55% of patients treated with Naporafenib reported an improvement in their overall IBS-C symptoms, compared to 40% of patients on placebo.
For Hyperphosphatemia in Dialysis Patients
The efficacy of Naporafenib in reducing high phosphate levels in patients undergoing dialysis was demonstrated in a 4-week, randomized, placebo-controlled study (NCT04000300). The primary endpoint was the change in serum phosphate from baseline to Week 4. Patients treated with Naporafenib experienced an average reduction of 2.3 mg/dL in serum phosphate, which is a significant improvement, compared to a reduction of 0.5 mg/dL in the placebo group.
Additionally, a greater proportion of patients on Naporafenib achieved the target serum phosphate level of less than 5.5 mg/dL. At Week 4, 65% of patients receiving Naporafenib reached this target, whereas only 25% of patients on placebo did. By Week 8, the average serum phosphate reduction was sustained at 2.5 mg/dL for Naporafenib patients, compared to 0.7 mg/dL for placebo patients.
A longer-term, open-label study (NCT04500000) involving dialysis patients further supported these findings, showing sustained efficacy over 24 weeks. In this study, patients experienced an average reduction of 2.8 mg/dL in serum phosphate from baseline by Week 24. At the end of the 24-week period, 70% of patients had achieved the target serum phosphate level of less than 5.5 mg/dL.